Search
-
Thomas Smeenk of Hemostemix Announces a Convertible Debenture Offering, an Equity Financing Update, and Spin-out Plans
In this InvestorIntel interview during PDAC 2023, Tracy Weslosky talks to Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF)…
-
Hemostemix Unit Offering Repriced
March 8, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) announces it is repricing its…
-
Hemostemix Offers up to 500 6% Convertible Debentures, Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval
March 7, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“HEM” or the “Company”) is…
-
Hemostemix Plans to Revolutionize Stem Cell Therapy with Scalable Production and New Sales Goals
Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) has developed an effective “stem cell therapy” for…
-
Hemostemix Announces Unit Private Placement
February 1, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a…
-
The Force Family Office Engaged by Hemostemix
January 31, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
-
Hemostemix’ “Your Fountain of Youth” Trademark Granted by Switzerland
January 30, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
-
Hemostemix’ “Your Fountain of Youth” Trademark Granted by Japan Patent Office
January 26, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
-
Hemostemix Wins Arbitration Decision
January 24, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
-
Hemostemix Hiring 4 New Biotechnologists in Montreal and Appling for Grants to Fund Up To 75% of 5-Year Costs
January 23, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…